What You Should Know:
– Outcomes4Me Inc., a Cambridge, MA-based developer of an Artificial Intelligence (AI)-powered platform to empower cancer patients to navigate their care, today announced it has raised $12 million in an oversubscribed Series A round led by Northpond Ventures, with participation from all existing investors, including Sierra Ventures, Asset Management Ventures, Merstal Ltd, IRA Capital, and others. Andrea Jackson, a Northpond Ventures Director, will join Outcomes4Me’s board.
– After experiencing first-hand the challenges of being a patient, Dr. Said, a former Senior Vice President and Global Head of Oncology Policy and Market Access at Novartis, co-founded Outcomes4Me in 2017, with the company’s Chief Medical Advisor, Dr. Osama Rahma, a National Institutes of Health (NIH)-trained practicing oncologist at Dana-Farber Cancer Institute and the Clinical Director of its Center for Cancer Therapeutic Innovation. They were later joined by Chief Operating Officer Sami Shalabi, a former Google executive who sold his company to Google and co-founded and led Google Play Newsstand and the all-new Google News, growing both to over a billion users.
– Outcomes4Me helps patients navigate their cancer treatment journey using a personalized approach that provides the appropriate evidence-based information when patients need it most. Outcomes4Me uses a sophisticated collection of AI and natural language processing (NLP) techniques to personalize information for each patient, factoring in their clinical histories, personal preferences and broader context. The platform’s AI-powered personalization unlocks an adaptive experience that empowers patients to stay informed, understand their treatment options, find clinical trials, manage their quality of life, and ultimately advocate for themselves.
– Funds will be used to extend Outcomes4Me’s platform beyond breast cancer to other cancers, grow the platform’s regulatory-grade dataset, and expand to more patients in Europe. In less than three years, the company has achieved significant market penetration and repeat engagement with breast cancer patients across more than 1,000 medical institutions in all 50 U.S. states and five Canadian provinces.
